HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Codex Health Claims Guides Development Renewed By Nutrition Committee

This article was originally published in The Tan Sheet

Executive Summary

The Codex Alimentarius Committee on Nutrition & Foods for Special Dietary Uses (CCNFSDU) is planning to initiate "new work" on the elaboration of proposed draft recommendations on the scientific basis for health claims, according to a recently-released Codex report

You may also be interested in...



Codex Review Of Infant Formula Pathogen Contamination Sought By U.S.

The U.S. is requesting that the Codex Committee on Nutrition & Foods for Special Dietary Uses (CCNFSDU) address concerns related to the presence of pathogens in infant formula

Infant Formula Nutrient Levels Addressed In U.S. Codex Draft Position

Essential nutrient minimum levels in infant formulas should be based on the mean levels found in breast milk, while maximum amounts should be set "when there is evidence of adverse health effects at higher levels," according to the draft position on infant formula proposed by the U.S. delegation to the Codex Alimentarius

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS129288

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel